we’re programs. commercial regards discussing status vibegron vibegron the overactive quarter activities and as of call make well our XXXX, to our In be you, over the as clinical for I’ll in upcoming pivotal agency anticipated continue today’s to the expected our In start Thank With remain engaged Urovant call launch towards until Drug history, commercial and continue to actively preparing FDA thanks fiscal work of reaching we for of XXXX. December the company’s quarter the our late progress of just joining Ryan, this and New with the of approval preparing XX. and of track on bladder. vibegron strong month today. commercial a for for we to the all first in our regulatory period to second PDUFA in you as Application, date advancing of interactions the launch continued our with
market provide with hiring you Now marketing of co-promotion update our plans. our and me the force, let our our on access an agreement with sales activities Sunovion,
is to the space. sales of XX XX of combined a terms with force, and in experience years say our average I’m nearly pharmaceutical XXX board. has Urovant, and urology hired industry years this sales in In team that pleased to and been proficiency an significant of on our the of of knowledge of leadership amount team experience brings individuals
process the significant XXX for in sales the our approximately approximately at care sales highly the and of combined market. now of overactive the with recruiting force. of of the XX urology we’ll have representatives share these received representatives our very we in pleased applicants. and from highest We’re segments this voice effort for qualified care I’m that specialty force long-term With urology interest level sales launch, bladder long-term
signed million from invest March vibegron more that XXXX. marketing the than care Sunovion’s consider Sunovion top call our will you of through with multi-specialty when of sales sales factor primary efforts the specialty all primary agreement, force a Primary Under enable represent and this XX% will And Care force the urology agreement to further care into sales Our medium- in space, Sunovion. and important also an approximately co-promotion care on in providers in activities to overactive is of XX $XX prescriptions This Physicians. our prescribing primary us augment high-prescribing recently expand providers. bladder. we launch will
We expect without us segment market, need reach our of this to this for critical amplifying to significant the by the within value deploy create agreement additional capital.
Since These Now, discuss we been demonstrated on as been well key provide August, to proposition market meetings meeting our access. let These exchange efforts efficacy you pivotal them meetings. believe the have launch. our introduce as we given data prepare beneficial if payers, vibegron with for with has access meetings value vibegron me pre-approval and to trial, our the will teams vibegron safety that clinical as that have market and payers an the on and in provide opportunity EMPOWUR update approved. educate have information us through
our to shifting marketing Now efforts.
supported campaign. marketing teams play communications health sales partnerships. healthcare consumer engage alike, non-branded through launched an all and will whom provider platform digital in multichannel be Our various patients will We’ve by care of efforts. This an role providers, payers our and launch important extensive
has have stakeholders key on and response sales educate Additionally, leaders our been our positive. pipeline very engaged to the further and company them
call, very today. the around With accepted lot. more and alternative on each better bladderchatter.com The last from and that overactive sites virtual we’ve launched registrations, community, and shared we’ve normal. Through bladderchatter.com where bladder which individual to with XXX,XXX bladder often a this approximately learned from dialogue is summer. it’s this a change learn suffering available we our virtual people community and help bladder, are discuss too can clear of forum as than unbranded their the provides other is As you seeking often community what’s people to overactive XX,XXX issues over purpose an stigmatized overactive visits a concerns. misunderstood,
contribution commercialize many that we have overactive treatment. on XX% a or approval. their doctor Some key are hope best-in-class potentially and XX% very patients. to to a we’re insights alleviating with by bladder not believe bothered make significant that FDA’s symptoms In of to currently XX% include pending By treatment, symptoms market to for well-prepared these the successfully bringing the bothered vibegron summary, we discussed their overactive bladder. are of
briefly over moment. a on which will more me to pipeline, Cornelia detail development get our in let into transition Now then
progress of ongoing its of the a in value number with bladder. overactive indication beyond pleased designed made we’ve maximize programs for to the We’re initial vibegron
COURAGE treat X and study developing is BPH. overactive men the program, clinical lead to vibegron with bladder Our
We’re half continuing results second of and study into this patients XXXX. expect top-line to in enroll the
Our pain. currently program is coming the treatment vibegron clinical our syndrome expect have study for bowel We program results top-line for to this in second irritable a of Xa for Phase weeks.
Chief have novel X from are to for second our trial. a pharmacological we program, Board Xa Regarding on OAB oral cohort patients to occur URO-XXX, turn expected overactive therapy opening into Data failed development bladder, our early the treatment and Monitoring to for cohort let to Officer, Cornelia be gene X, over of is to now me will XXXX. injectable made or Independent DSMB the who from call recommendation move Haag-Molkenteller. concludes Dr. continuing in enroll my This Phase the And decision The therapy Medical our the Safety remarks.
